Nasdaq:KPTI
Karyopharm Therapeutics Inc.
Karyopharm Therapeutics leverages a unique drug delivery platform to advance next-generation cancer therapies across oncology and orphan disease markets.
Key Metrics
Investment Thesis
Bull Case
Investors may consider KPTI for its differentiated asset profile in oncology, where its oral delivery technology offers a distinct advantage over competitors reliant on traditional IV therapies. The company's existing commercial franchise provides a foundation for revenue stability while the pipeline targets high-growth orphan markets with favorable regulatory incentives. Strategic partnerships and licensing deals offer potential non-dilutive capital injections to fund further development.
Bear Case
The stock is vulnerable due to widening annual losses reaching $196M and a massive accumulated deficit of $1.76B that threatens long-term solvency without successful commercial milestones. High operating expenses coupled with minimal capital expenditures suggest the company is in an expensive growth phase with no immediate path to profitability. Dependence on external funding sources increases dilution risk for existing shareholders given the negative cash flow from operations.
About Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc. (KPTI) is a biotechnology company developing novel cancer therapies and orphan drug candidates using its proprietary drug delivery platform. The company operates primarily in the United States and Europe, focusing on oncology and rare disease indications to address unmet medical needs. With a diverse pipeline of oral and injectable formulations, Karyophaim aims to transform patient treatment options for hematologic malignancies and other serious conditions.
Analysis
Management Discussion
Recent financial performance shows a significant deterioration in profitability with net losses widening to $196M in 2025 compared to $76M in 2024, despite stable revenue around $146M. Operating expenses surged to $236.8M, heavily influenced by research and development costs of $125.6M and general administrative expenses exceeding $100M. While cash reserves remain robust at $60.9M, the negative operating cash flow of $75.4M indicates continued heavy investment in pipeline expansion.
Industry Overview
The biotechnology sector is currently characterized by intense competition and high barriers to entry, with a heavy emphasis on R&D investment to secure FDA approvals and patent protection. Companies in oncology are navigating complex pricing negotiations and market access challenges while striving to differentiate their therapies against established standards of care. The orphan drug sub-sector offers lucrative incentives but requires successful proof-of-concept in small patient populations to achieve commercial viability.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $157.1M | $146.0M | $145.2M | $146.1M |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $157.1M | $146.0M | $145.2M | $146.1M |
| Operating Expenses | $299.3M | $275.6M | $264.7M | $236.8M |
| Operating Income | $-142.2M | $-129.5M | $-119.4M | $-90.7M |
| R&D | $148.7M | $138.8M | $143.2M | $125.6M |
| G&A | $145.4M | $131.9M | $115.4M | $105.2M |
| Stock-Based Comp | $35.4M | $21.7M | $18.4M | $14.1M |
| Depreciation | $621.0K | $530.0K | $340.0K | $296.0K |
| Other OpEx | $5.2M | $4.9M | $6.0M | $5.9M |
| Non-Operating Income | $-22.7M | $-13.2M | $43.1M | $-105.3M |
| Interest Expense | $25.0M | $23.8M | — | — |
| Interest Income | $2.4M | $10.9M | $7.4M | $2.8M |
| Pre-Tax Income | $-164.9M | $-142.8M | $-76.4M | $-196.0M |
| Income Tax | $369.0K | $323.0K | $57.0K | $43.0K |
| Continuing Ops | $-165.3M | $-143.1M | $-76.4M | $-196.0M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-165.3M | $-143.1M | $-76.4M | $-196.0M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-165.3M | $-143.1M | $-76.4M | $-196.0M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $350.2M | $233.9M | $156.5M | $103.1M |
| Cash & Equivalents | $135.2M | $52.2M | $62.5M | $60.5M |
| Inventory | $4.2M | $3.0M | $4.7M | $4.0M |
| Prepaid Expenses | $19.8M | $11.8M | $12.2M | $9.2M |
| Other Current Assets | $190.9M | $166.8M | $77.0M | $29.4M |
| Long-Term Assets | $8.0M | $6.5M | $7.9M | $5.3M |
| PP&E (Net) | $1.1M | $606.0K | $400.0K | $104.0K |
| Operating Leases | $6.2M | $4.3M | $5.9M | $4.5M |
| Other LT Assets | $633.0K | $1.6M | $1.6M | $618.0K |
| Total Assets | $358.2M | $240.4M | $164.4M | $108.4M |
| Current Liabilities | $65.9M | $69.5M | $92.3M | $92.1M |
| Accounts Payable | $2.8M | $3.1M | $5.1M | $4.0M |
| Current Leases | $2.9M | $3.3M | $438.0K | $969.0K |
| Other Current Liab | $1.8M | $1.7M | $26.1M | $22.6M |
| Long-Term Liabilities | $308.9M | $307.2M | $258.2M | $309.3M |
| LT Operating Leases | $6.1M | $2.8M | $6.7M | $5.7M |
| Other LT Liab | $302.8M | $304.4M | $251.5M | $303.5M |
| Total Liabilities | $374.8M | $376.6M | $350.4M | $401.3M |
| Shareholders' Equity | $-16.7M | $-136.2M | $-186.0M | $-292.9M |
| Retained Earnings | $-1.34B | $-1.49B | $-1.56B | $-1.76B |
| AOCI | $-638.0K | $-161.0K | $-356.0K | $71.0K |
| Total L&E | $358.2M | $240.4M | $164.4M | $108.4M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-165.3M | $-143.1M | $-76.4M | $-196.0M |
| Non-Cash Adjustments | $13.1M | $74.0M | $-63.2M | $112.1M |
| Working Capital Changes | $2.6M | $-23.6M | $12.1M | $8.5M |
| Cash from Operations | $-149.6M | $-92.7M | $-127.5M | $-75.4M |
| Capital Expenditures | $118.0K | $0 | $142.0K | $0 |
| Cash from Investing | $-104.3M | $7.9M | $95.5M | $43.4M |
| Cash from Financing | $193.7M | $1.1M | $41.6M | $30.0M |
| FX Effect | $-488.0K | $-34.0K | $-11.0K | $20.0K |
| Net Change in Cash | $-60.6M | $-83.7M | $9.6M | $-1.9M |
| Beginning Cash | $197.4M | $136.9M | $53.2M | $62.8M |
| Ending Cash | $136.9M | $53.2M | $62.8M | $60.9M |
Frequently Asked Questions
How does Karyopharm Therapeutics Inc. make money?
The company's revenue streams are driven by its oncology franchise, which includes approved products like Talazoparib (Talzenna) and Naxitamab (Zinplava), as well as orphan drug programs targeting rare genetic disorders. Revenue is generated through product sales, licensing agreements with partners, and royalties from commercialized assets in specific geographic regions.
What are the main risks for KPTI?
The company faces substantial clinical trial risks associated with its late-stage development programs that could fail or face regulatory delays. Cash burn remains a critical concern given the negative net income of $196M and accumulated retained earnings deficit, creating pressure on liquidity reserves. Regulatory scrutiny regarding orphan drug exclusivity periods and market access negotiations in key regions like the US and EU poses potential revenue volatility.
What is KPTI's competitive advantage?
Karyopharm's primary moat lies in its proprietary ALCANEX™ drug delivery platform, which enables the development of oral formulations for drugs that were previously only available as intravenous injections. Additionally, the company benefits from a differentiated pipeline focused on high-value oncology indications with significant unmet medical needs and strategic licensing partnerships that provide cash flow support.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.